Quantification of HDL particle concentration by calibrated ion mobility analysis

Patrick M. Hutchins, Graziella E. Ronsein, Jeffrey S. Monette, Nathalie Pamir, Jake Wimberger, Yi He, G. M. Anantharamaiah, Daniel Seung Kim, Jane E. Ranchalis, Gail P. Jarvik

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

BACKGROUND: It is critical to develop new metrics to determine whether HDL is cardioprotective in humans. One promising approach is HDL particle concentration (HDL-P), the size and concentration of HDL in plasma. However, the 2 methods currently used to determine HDL-P yield concentrations that differ >5-fold. We therefore developed and validated an improved approach to quantify HDL-P, termed calibrated ion mobility analysis (calibrated IMA).

METHODS: HDL was isolated from plasma by ultracentrifugation, introduced into the gas phase with electrospray ionization, separated by size, and quantified by particle counting. We used a calibration curve constructed with purified proteins to correct for the ionization efficiency of HDL particles.

RESULTS: The concentrations of gold nanoparticles and reconstituted HDLs measured by calibrated IMA were indistinguishable from concentrations determined by orthogonal methods. In plasma of control (n=40) and cerebrovascular disease (n = 40) participants, 3 subspecies of HDL were reproducibility measured, with an estimated total HDL-P of 13.4 (2.4) μmol/L. HDL-C accounted for 48% of the variance in HDL-P. HDL-P was significantly lower in participants with cerebrovascular disease (P=0.002), and this difference remained significant after adjustment for HDL cholesterol concentrations (P = 0.02).

CONCLUSIONS: Calibrated IMA accurately determined the concentration of gold nanoparticles and synthetic HDL, strongly suggesting that the method could accurately quantify HDL particle concentration. The estimated stoichiometry of apolipoprotein A-I determined by calibrated IMA was 3-4 per HDL particle, in agreement with current structural models. Furthermore, HDL-P was associated with cardiovascular disease status in a clinical population independently of HDL cholesterol.

Original languageEnglish (US)
Pages (from-to)1393-1401
Number of pages9
JournalClinical Chemistry
Volume60
Issue number11
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Cerebrovascular Disorders
Ions
Plasmas
Particle Size
Gold
Nanoparticles
HDL Cholesterol
HDL3 Lipoprotein
Electrospray ionization
Structural Models
Ultracentrifugation
Apolipoprotein A-I
Stoichiometry
Calibration
Ionization
Cardiovascular Diseases
Gases
Population
Proteins

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hutchins, P. M., Ronsein, G. E., Monette, J. S., Pamir, N., Wimberger, J., He, Y., ... Jarvik, G. P. (2014). Quantification of HDL particle concentration by calibrated ion mobility analysis. Clinical Chemistry, 60(11), 1393-1401. https://doi.org/10.1373/clinchem.2014.228114

Quantification of HDL particle concentration by calibrated ion mobility analysis. / Hutchins, Patrick M.; Ronsein, Graziella E.; Monette, Jeffrey S.; Pamir, Nathalie; Wimberger, Jake; He, Yi; Anantharamaiah, G. M.; Kim, Daniel Seung; Ranchalis, Jane E.; Jarvik, Gail P.

In: Clinical Chemistry, Vol. 60, No. 11, 01.11.2014, p. 1393-1401.

Research output: Contribution to journalArticle

Hutchins, PM, Ronsein, GE, Monette, JS, Pamir, N, Wimberger, J, He, Y, Anantharamaiah, GM, Kim, DS, Ranchalis, JE & Jarvik, GP 2014, 'Quantification of HDL particle concentration by calibrated ion mobility analysis', Clinical Chemistry, vol. 60, no. 11, pp. 1393-1401. https://doi.org/10.1373/clinchem.2014.228114
Hutchins, Patrick M. ; Ronsein, Graziella E. ; Monette, Jeffrey S. ; Pamir, Nathalie ; Wimberger, Jake ; He, Yi ; Anantharamaiah, G. M. ; Kim, Daniel Seung ; Ranchalis, Jane E. ; Jarvik, Gail P. / Quantification of HDL particle concentration by calibrated ion mobility analysis. In: Clinical Chemistry. 2014 ; Vol. 60, No. 11. pp. 1393-1401.
@article{a772dcf8f5e541398f12340210fb8b93,
title = "Quantification of HDL particle concentration by calibrated ion mobility analysis",
abstract = "BACKGROUND: It is critical to develop new metrics to determine whether HDL is cardioprotective in humans. One promising approach is HDL particle concentration (HDL-P), the size and concentration of HDL in plasma. However, the 2 methods currently used to determine HDL-P yield concentrations that differ >5-fold. We therefore developed and validated an improved approach to quantify HDL-P, termed calibrated ion mobility analysis (calibrated IMA).METHODS: HDL was isolated from plasma by ultracentrifugation, introduced into the gas phase with electrospray ionization, separated by size, and quantified by particle counting. We used a calibration curve constructed with purified proteins to correct for the ionization efficiency of HDL particles.RESULTS: The concentrations of gold nanoparticles and reconstituted HDLs measured by calibrated IMA were indistinguishable from concentrations determined by orthogonal methods. In plasma of control (n=40) and cerebrovascular disease (n = 40) participants, 3 subspecies of HDL were reproducibility measured, with an estimated total HDL-P of 13.4 (2.4) μmol/L. HDL-C accounted for 48{\%} of the variance in HDL-P. HDL-P was significantly lower in participants with cerebrovascular disease (P=0.002), and this difference remained significant after adjustment for HDL cholesterol concentrations (P = 0.02).CONCLUSIONS: Calibrated IMA accurately determined the concentration of gold nanoparticles and synthetic HDL, strongly suggesting that the method could accurately quantify HDL particle concentration. The estimated stoichiometry of apolipoprotein A-I determined by calibrated IMA was 3-4 per HDL particle, in agreement with current structural models. Furthermore, HDL-P was associated with cardiovascular disease status in a clinical population independently of HDL cholesterol.",
author = "Hutchins, {Patrick M.} and Ronsein, {Graziella E.} and Monette, {Jeffrey S.} and Nathalie Pamir and Jake Wimberger and Yi He and Anantharamaiah, {G. M.} and Kim, {Daniel Seung} and Ranchalis, {Jane E.} and Jarvik, {Gail P.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1373/clinchem.2014.228114",
language = "English (US)",
volume = "60",
pages = "1393--1401",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Quantification of HDL particle concentration by calibrated ion mobility analysis

AU - Hutchins, Patrick M.

AU - Ronsein, Graziella E.

AU - Monette, Jeffrey S.

AU - Pamir, Nathalie

AU - Wimberger, Jake

AU - He, Yi

AU - Anantharamaiah, G. M.

AU - Kim, Daniel Seung

AU - Ranchalis, Jane E.

AU - Jarvik, Gail P.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - BACKGROUND: It is critical to develop new metrics to determine whether HDL is cardioprotective in humans. One promising approach is HDL particle concentration (HDL-P), the size and concentration of HDL in plasma. However, the 2 methods currently used to determine HDL-P yield concentrations that differ >5-fold. We therefore developed and validated an improved approach to quantify HDL-P, termed calibrated ion mobility analysis (calibrated IMA).METHODS: HDL was isolated from plasma by ultracentrifugation, introduced into the gas phase with electrospray ionization, separated by size, and quantified by particle counting. We used a calibration curve constructed with purified proteins to correct for the ionization efficiency of HDL particles.RESULTS: The concentrations of gold nanoparticles and reconstituted HDLs measured by calibrated IMA were indistinguishable from concentrations determined by orthogonal methods. In plasma of control (n=40) and cerebrovascular disease (n = 40) participants, 3 subspecies of HDL were reproducibility measured, with an estimated total HDL-P of 13.4 (2.4) μmol/L. HDL-C accounted for 48% of the variance in HDL-P. HDL-P was significantly lower in participants with cerebrovascular disease (P=0.002), and this difference remained significant after adjustment for HDL cholesterol concentrations (P = 0.02).CONCLUSIONS: Calibrated IMA accurately determined the concentration of gold nanoparticles and synthetic HDL, strongly suggesting that the method could accurately quantify HDL particle concentration. The estimated stoichiometry of apolipoprotein A-I determined by calibrated IMA was 3-4 per HDL particle, in agreement with current structural models. Furthermore, HDL-P was associated with cardiovascular disease status in a clinical population independently of HDL cholesterol.

AB - BACKGROUND: It is critical to develop new metrics to determine whether HDL is cardioprotective in humans. One promising approach is HDL particle concentration (HDL-P), the size and concentration of HDL in plasma. However, the 2 methods currently used to determine HDL-P yield concentrations that differ >5-fold. We therefore developed and validated an improved approach to quantify HDL-P, termed calibrated ion mobility analysis (calibrated IMA).METHODS: HDL was isolated from plasma by ultracentrifugation, introduced into the gas phase with electrospray ionization, separated by size, and quantified by particle counting. We used a calibration curve constructed with purified proteins to correct for the ionization efficiency of HDL particles.RESULTS: The concentrations of gold nanoparticles and reconstituted HDLs measured by calibrated IMA were indistinguishable from concentrations determined by orthogonal methods. In plasma of control (n=40) and cerebrovascular disease (n = 40) participants, 3 subspecies of HDL were reproducibility measured, with an estimated total HDL-P of 13.4 (2.4) μmol/L. HDL-C accounted for 48% of the variance in HDL-P. HDL-P was significantly lower in participants with cerebrovascular disease (P=0.002), and this difference remained significant after adjustment for HDL cholesterol concentrations (P = 0.02).CONCLUSIONS: Calibrated IMA accurately determined the concentration of gold nanoparticles and synthetic HDL, strongly suggesting that the method could accurately quantify HDL particle concentration. The estimated stoichiometry of apolipoprotein A-I determined by calibrated IMA was 3-4 per HDL particle, in agreement with current structural models. Furthermore, HDL-P was associated with cardiovascular disease status in a clinical population independently of HDL cholesterol.

UR - http://www.scopus.com/inward/record.url?scp=84908648021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908648021&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2014.228114

DO - 10.1373/clinchem.2014.228114

M3 - Article

VL - 60

SP - 1393

EP - 1401

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -